Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 14Terminated 4Withdrawn 1Unknown 1Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 15Other hematologic neoplasm 12CNS 9Genitourinary 8Plasma cell 7Breast 7Myeloid 4Thoracic 3Gynecologic 3Sarcoma 1Other solid neoplasm 1Head & Neck 1Gastrointestinal 1Dermatologic 1Classical hematology 1

Conditions

Liver Neoplasms 1Gallbladder Neoplasms 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1

Interventions

Oxaliplatin 283Capecitabine 217Fluorouracil 210Irinotecan 145Leucovorin 136Gemcitabine 121S 1 (combination) 110apatinib 108Cisplatin 99Radiotherapy 97Bevacizumab 97Drug Therapy 94Paclitaxel 93camrelizumab 88sintilimab 77Cetuximab 74lenvatinib 60Neoadjuvant Therapy 59tislelizumab 54Surgical Procedures, Operative 54Sorafenib 53Folfox protocol 52Docetaxel 51toripalimab 50130-nm albumin-bound paclitaxel 45Laparoscopy 41HMPL-013 40XELOX 38Albumin-Bound Paclitaxel 36regorafenib 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Filgrastim × Gastrointestinal × Clear all
NCT00003296 2013-12-19

Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
26 enrolled
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡